CDH1 Testing: Can it Predict the Prophylactic or Therapeutic Nature of Total Gastrectomy in Hereditary Diffuse Gastric Cancer? by Ziogas, Dimosthenis & Roukos, Dimitrios H.
EDITORIAL
CDH1 Testing: Can it Predict the Prophylactic or Therapeutic
Nature of Total Gastrectomy in Hereditary Diffuse Gastric
Cancer?
Dimosthenis Ziogas, MD
1 and Dimitrios H. Roukos, MD
2
1Department of Surgery, Ioannina University Hospital, Ioannina, Greece;
2Department of Surgery, Personalized Cancer
Medicine, Biobank, Ioannina University, Ioannina, Greece
Gastric cancer has a poor prognosis. Primary preven-
tion is a major goal to reduce incidence and mortality, but
it is still an illusion. There is an exception: the rare
hereditary diffuse gastric cancer (HDGC). This syndrome
can be both accurately predicted and successfully pre-
vented. How?
If we could identify high-risk individuals in the general
population and subsequently tailor an effective preventive
intervention, then we could protect them by saving their
lives. This achievement is now realistic, although it con-
cerns a small only fraction of cases. Genetic testing in
individuals with a family history of diffuse gastric cancer
allows for identiﬁcation of family members with inherited
mutations at CDH1 gene. These mutation carriers have a
very high risk of developing diffuse gastric cancer
1 and
women have an additional lobular breast cancer risk.
2 This
HDGC syndrome is characterized by early onset and
requires primary prevention at a young age.
1,2
Because the mortality risk in patients diagnosed at
advanced tumor stage is very high in the west, and there is
no standard screening method to identify accurately the
disease in CDH1 mutation carriers at early stage,
3
prophylactic total gastrectomy (PTG) has been
recommended.
4
However, the number of patients with disease-causing
CDH1 mutations published who have undergone PTG is
very small. Is PTG an experimental approach? Why is it
that CDH1 mutation positive testing can be considered a
surrogate predictor of the presence of occult signet-ring-
cells/diffuse gastric cancer? The decision for PTG at a
young age is too hard given the aggressiveness and
adverse effects of total gastrectomy on quality of life
(QOL). However, if the predictive power is very high
and indicative of microscopic cancer foci undetectable
by any other current imaging or endoscopic screening
technique, then the decision for therapeutic rather than
prophylactic total gastrectomy is much more convincing.
If the decision for surgery is made, then why is total
chosen and not subtotal or partial gastrectomy? If a
patient is diagnosed with a small diffuse gastric cancer
in antrum and at the same time carries CDH1 mutations
is the current standard subtotal gastrectomy sufﬁcient
procedure especially for him or a total gastrectomy is
required and why?
The E-cadherin protein encoded by the CDH1 gene is
important in the molecular connections between adjacent
cells in the stomach, breast, and other areas of the body.
Loss of E-cadherin function, associated with CDH1
mutations, is observed in diffuse-type gastric cancer and
invasive lobular breast cancer. Penetrance estimates sug-
gest that individuals with E-cadherin germline mutations
face a lifetime risk of approximately 75% of developing
diffuse gastric cancer and women have an additional 39%
risk of developing lobular breast cancer.
1,2
Adenocarcinomas of the stomach are distinguished into
intestinal-type and diffuse-type cancer. Approximately
40 years after this classiﬁcation introduced by Lauren, a
recent genome-wide association (GWA) study conﬁrmed
that the intestinal and diffuse types are two distinctly
different subtypes of gastric cancer.
5 The intestinal type
appears to be associated with Helicobacter pylori infec-
tion, which may lead to atrophic gastritis, intestinal
 Society of Surgical Oncology 2009
Published Online: 28 July 2009
D. H. Roukos, MD
e-mail: droukos@cc.uoi.gr
Ann Surg Oncol (2009) 16:2678–2681
DOI 10.1245/s10434-009-0598-ymetaplasia, dysplasia, and invasive adenocarcinoma, and
is particularly common in some high-risk geographic
regions, including Japan. By contrast, the diffuse-type
develops through a different pathway. The genetic back-
ground is more important than for the intestinal type and
appears unrelated to the presence of H. pylori.
3 The Study
Group of Millennium Genome Project for Cancer identi-
ﬁed through this new GWA study that genetic variants
(SNPs) at PSCA gene are associated with a small
increased relative risk (\2) of sporadic diffuse gastric
cancer.
5
HERITABILITY AND ENVIRONMENT
INTERACTIONS NETWORKS
Cancer initiation and metastasis are extremely more
complicated biological processes than we had previously
imagined. Most recent extensive genetic studies and GWA
studies have revealed that a tremendous number of disease-
causing variants at multiple genes contribute to carcino-
genesis.
6 However, each of these alterations confers a
modest only relative risk (RR\2); thus, at present this
information is unreliable for the clinic for common com-
plex disease as well as for gastric cancer.
7
The future clinical success of cancer treatment is
uncertain if no realistic innovation appears. Despite
enthusiasm with the next generation whole-genome scans
for faster and cheaper completion of the genetic catalogue
of individual cancer types, multiple hurdles should be
overcome. For example, the functional role of genes, pro-
teins and other small molecules, including miRNAs has to
be elucidated. Particularly the understanding of their
interactions networks as well as the gene-environment
interaction is currently beyond researcher’s and clinician’s
comfort. Currently, there is no standard model to under-
stand the extremely complex causal networks feedbacks
loops. In an effort to map the genotype-phenotype rela-
tionship, the most popular model used is the Bayesian
network model, but it is associated with a series of
limitations.
8
Mathematical or computational (in silico) models to
predict genetic or transcripts interactions (transcriptome),
intracellular signalling pathways proteins interactions
(interactome), and interactions between primary tumor
cells and stromal cells (microenvironment) are under
development.
9 However, these predictions are beyond the
current state-of-the-art. It has become clear that not only a
wide spectrum of phenotypic cancer diversity exists, but
also the underlying genetic basis varies widely even
among patients with the same tumor type and similar
conventional clinicopathologic features. There has been a
clearly nonlinear relationship between DNA changes and
cancer phenotype.
8 This complexity to predict phenotypic
cancer diversity by genotyping explains the current limi-
tation in development of both rousts biomarkers and
molecularly targeting agents toward innovative personal-
ized cancer management.
8,9
In sharp contrast to the current limitations of predicting
causal networks for sporadic cancer (no family history),
heritable mutations at only one speciﬁc gene (CDH1) can
cause diffuse gastric cancer. Most CDH1 mutation carriers
will develop diffuse gastric cancer. This relatively simple
and nearly linear relationship between CDH1 and pheno-
type (diffuse gastric cancer) allows genetic testing for
identifying CDH1 mutation carriers. Once a mutations
carrier has been identiﬁed, which is the optimal medical
intervention?
TOTAL GASTRECTOMY IN CDH1 MUTATION
CARRIERS: PROPHYLACTIC OR THERAPEUTIC?
Prophylactic total gastrectomy has been recommended
for CDH1 mutation carriers; however, the published data
are still limited. Plausible explanations for rare perfor-
mance of PTG include: 1) physicians and public
community are less aware on HDGC; 2) mutation carriers
are rarely found in the general population and account for
approximately 3–5% among patients diagnosed with gas-
tric cancer.
6 it is difﬁcult to convince ‘‘healthy’’ young
individuals to undergo total gastrectomy and live a long
time ‘‘without stomach.’’ Indeed, complete removal of the
stomach maybe associated with postoperative morbidity
and adverse effects in QOL. However, if CDH1 mutation
testing could be a sole surrogate predictor of the presence
of microscopic disease, then it might change the decision
from prophylactic to therapeutic total gastrectomy.
To evaluate further all of these issues, Hebbard and
colleagues reported the results of a retrospective study on
PTG published in the July 2009 issue of the Annals of
Surgical Oncology.
10 Twenty-three patients from the
Canadian province of Newfoundland and Labrador under-
went PTG between February 2006 and November 2008.
All of these individuals were conﬁrmed to have a trun-
cating mutation of the CDH1 gene. The median age at the
time of surgery was 45 (range 26–63) years. The patients
came from three different kindreds, two of which shared
the same 2398delC mutation of exon 15 of CDH1. The
third family carried 1189A[T mutation in exon 9 of
CDH1.
Preoperative endoscopy and mucosal biopsies revealed
the disease in only 2 of 23 patients (9%). Interestingly, ﬁnal
standardized pathological evaluation of TG specimens
showed evidence of diffuse/signet-ring-cell carcinoma in
22 of 23 (96%) patients.
Total Prophylactic Gastrectomy in CDH1 Mutation 2679Despite its retrospective nature, the study by Hebbard
and colleagues
10 has important clinical implications. It
provides a series of advantages. First, it is the largest series
on PTG in HDGC prevention setting. Given the rarity of
the syndrome, the number of CDH1 mutation carriers
(n = 23) who consecutively underwent PTG within a rel-
ative short period (33 months) is reported for the ﬁrst time.
How can this large number of PTG in this study in the
Canadian province of Newfoundland be explained? This
region, according to recent estimates, has one of the highest
HDGC rate due to both founder and independent muta-
tions; approximately 40% of all gastric cancer cases are
hereditary gastric cancer compared with less than 5% in
North America.
2,4
Second, it conﬁrms that in the vast majority of cases,
mutation carriers already had microscopic intramucosal
disease, which explains the small (9%) proportion of dis-
ease revealed by preoperative endoscopic screening.
Table 1 summarizes the results of PTG for the prevention
of HDGC. Although larger studies are required to conﬁrm
this very large rate of therapeutic gastrectomy among
CDH1 mutation carriers, the data available (Table 1)
strongly indicate the presence of intramucosal disease in
these individuals. Therefore, we can consider most ([90)
mutation carriers as patients and not healthy individuals
who will ever develop diffuse gastric cancer.
Why total and not partial gastrectomy? First, multifocal
microscopic disease is very common as demonstrated by
pathohistological data (Table 1). Second, high-quality
preclinical evidence suggests that the genetic basis of the
HDGC syndrome is so strong that earlier or later cancer
will arise in residual gastric epithelium. Therefore, sub-
total gastrectomy is not recommended. This fact also
should be considered for patients with a preoperative
diagnosis of diffuse gastric cancer and at the same time a
family history. If CDH1 testing is positive, total gas-
trectomy could be considered. It should be noted,
however, that clinical data supporting this preclinical
evidence are still scarce.
What is the optimal age for total gastrectomy? It is
unknown. Although a mean age of onset of 37 years is
reported in the literature, the wide age range for gastric
cancer diagnosis is between 16 and 82 years, which makes
it difﬁcult to counsel on screening starting age and the
more critical PTG age. Kaurah et al. recommend PTG
during the early 1920s for men and individualization for
women mutation carriers because of the dietary ramiﬁca-
tions of gastrectomy on pregnancy.
2 This is a careful
suggestion to save lives and is based on both the thera-
peutic nature of total gastrectomy in [90% of mutation
carriers, and the low sensitivity and failure of current
screening, including endoscopy, positron emission tomo-
graphic scanning, or chromoendoscopy-directed biopsies.
Because long-term results from larger studies are still
lacking, at present an individualized approach for timing of
total gastrectomy considering multiple variables should be
discussed with each CDH1 mutation carrier. For women
carriers, beyond the 75% diffuse gastric cancer, the addi-
tional 40% lifetime risk of lobular breast cancer should be
considered.
FUTURE EXPECTATIONS
During the years to come, total gastrectomy will remain
the preventive intervention of choice for family members
who test positive for heritable mutations at CDH1. Current
TABLE 1 Published data on prophylactic total gastrectomy among E-cadherin mutation carriers
Study Year Total gastrectomy
(no. of patients)
Pathology (no. of patients
with signet-ring cancer cells)
Multifocality
Hebbard et al. 2009 23 22/23 (96%) N/A
Lynch et al. 2008 17 13/17 (76.5%) N/A
Carneiro et al. 2004 9 9/9 5/9 (55.5%)
Barber et al. 2008 8 8/8 7/8 (87.5%)
Norton et al. 2007 6 6/6 6/6
Lewis et al. 2001 6 6/6 5/6 (83.3%)
Charlton et al. 2004 6 6/6 6/6
Huntsman et al. 2001 5 5/5
Chun et al. 2001 5 5/5 5/5
Medina-Franco et al. 2007 4 4/4 4/4
Newman et al. 2006 2 0/2 0
Chung et al. 2007 1 1/1 0/1
Francis et al. 2007 1 1/1 1/1
Total 93 86/93 (92.5%) 42/52 (80.8%)
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innovative research.
Interestingly, in the ﬁeld of clinical practice, laparo-
scopic or robotic surgery already provides exciting data for
improving QOL outcomes. Less postoperative pain, faster
recovery, shorter hospital stay, brisk return to professional
work, and substantially better aesthetic results are some of
the advantages of closed vs. open surgery. During the last
decade, rapid progression from laparoscopic-assisted distal
gastrectomy with mini-laparotomy to totally laparoscopic
distal gastrectomy without mini-laparotomy has occurred
and moved from pioneering in laparoscopic gastrectomy
countries, such as Korea and Japan, to the United States
and Europe. For totally laparoscopic total gastrectomy
(TLTG) required for CDH1 mutation carriers, the progress
is less rapid. However, with an explosion in technology
reﬁnement and increasing surgeon’s experience it is
expected that TLTG will be performed with safety and
effectivity in highly specialized institutions. Given that at
this very early stage, extensive lymphadenectomy is not
required, TLTG becomes easier. The rarity of the syn-
drome and the need for a multidisciplinary team, beyond
high-volume surgeons, including geneticists, gastroente-
rologists, oncologists, psychologists, and nutritionists,
makes it difﬁcult to provide high-quality management for
high-risk families besides a few Comprehensive Cancer
Centers.
In the ﬁeld of translational research, the endeavor is
focused on predicting and distinguishing among CDH1
mutation carriers the approximately 25% who will not
develop diffuse gastric cancer from the 75% who will be
diagnosed with invasive diffuse gastric. The most plausible
explanation is that genetic and nongenetic factors promote
or reverse the large effect of CDH1 mutated gene on
tumorigenesis. New resequencing and GWA studies will
probably identify the modiﬁer genes. However, the chal-
lenge will remain about how to predict the complex
interactions between these modiﬁer genes, between these
and mutated CDH1 gene, as well as between all of these
genes and environmental factors, including H. pylori
infection.
6
CONCLUSIONS
Genetic testing for identifying CDH1 mutation carriers
is a surrogate predictor of intramucosal presence of diffuse/
signet-ring cancer cells. This usually multifocal micro-
scopic disease is undetectable by current screening
technology. Although longer follow-up data from larger
studies are required, total gastrectomy may save the lives
of CDH1 mutation carriers. The therapeutic rather than
prophylactic nature of surgery in these disease-causing
mutation carriers is supported by the pathological evidence
of cancer foci in most of these ‘‘healthy’’ individuals. Yet,
the optimal timing of surgery is unknown. Because of early
onset, total gastrectomy is recommended at a young age.
Extensive discussion and counselling is needed on an
individualized basis to decide on the timing of surgery.
Because laparoscopic surgery is rapidly evolving, totally
laparoscopic total gastrectomy with its substantial QOL
advantages, more CDH1 mutation carriers can be con-
vinced of the beneﬁts of ‘‘prophylactic’’ surgery. Next-
generation sequencing, modern functional studies, and
systems biology provide promise for understanding com-
plex interactions between CDH1 mutated gene and low-
risk genetic and nongenetic modiﬁers. Integrating all
clinical and genetics-personal genomics data into proba-
bilistic predictive network models, we might be able to
distinguish high-risk from lower-risk for developing dif-
fuse gastric cancer among CDH1 mutation carriers. Such a
prediction may have important clinical implications.
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